Reviva is developing a portfolio of internally discovered next generation safe and effective therapeutic drugs. Our research programs are focused on the central nervous system (CNS), cardiovascular (CV), metabolic and inflammatory indications. We develop small molecule therapeutics using chemical genomics based technology platform and proprietary chemistries. Reviva's products are new chemical entities (NCEs), and are designed to be safe, highly potent, selective, and orally bioavailable for improved patient compliance. Our product candidates and their current status are summarized in the following chart.